Business Wire

DE-CSC

7.3.2019 15:02:12 CET | Business Wire | Press release

Share
CSC Alerts Companies to Increased DNS Hijacking

CSC joins the U.S. Department of Homeland Security’s Cybersecurity and Infrastructure Security Agency, the UK National Cyber Security Centre, and other leading security organizations—including Cisco® Talos, FireEye® , and Akamai—in alerting corporations and the public to the recent widespread, state-sponsored domain name system (DNS) hijacking attacks. The targets of these recent attacks include government, corporate, telecommunication, and infrastructure entities resulting in website and email redirection to collect sensitive information. We urge companies to stay vigilant and employ security protocols to reduce exposure.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190307005082/en/

DNS attacks can lead to criminals redirecting web traffic away from a legitimate site to a rogue site, putting customers and companies at great risk,” says Mark Flegg, product director for Security Services at CSC. “The recent attacks are complex and vicious, exploiting weaknesses in DNS infrastructure that many companies set up once, then neglect. We strongly advise clients to use the tools and recommendations available to get their digital infrastructure secure.”

In response to DNS hijacking risk and other cyber crime, CSC introduced CSC Security CenterSM in 2018. It’s an online interface powered by advanced proprietary algorithms designed to expose security blind spots across domain names, DNS, and digital certificates that make vital online brand assets susceptible to DNS hijacking, phishing, and distributed denial of service attacks.

“Domain and DNS hijacking are not new security threats, which is why we developed CSC Security Center and are encouraged that hundreds of the world's largest companies are using it to help protect these critical online elements that enable them to operate,” says CSC Digital Brand Services General Manager Mark Calandra. “The sophistication and impact of the recent wave of attacks serves as a wakeup call that effectively managing domain names, DNS, and digital certificates needs to be a critical component for enhancing the security posture of any company with an online presence.”

CSC Security Center proactively identifies business-critical domains, and monitors them continually to ensure they’re protected. This includes checking for registry- and registrar-level locks that prevent unauthorized changes, reviewing user permissions, and verifying that security-focused, enterprise-class DNS hosting and digital certificates are implemented.

“The new CSC Security Center was a welcome surprise,” says Altan Changezi, lead infrastructure architect at Manulife. “It very quickly allows me to see—at a high level—our overall digital asset configuration at CSC. This includes the status of our most vital domains, as well as the number of users with privileged access to our CSC-managed web portals. The tool allows us to make proactive decisions to take control of our assets, as well as secure our accounts.”

The constant identification and monitoring of vital domains alerting companies to security blind spots allows them to take quick action to reduce real-world online threats to their web presence, customer data, and business-critical functions.

“CSC Security Center has shown us where we needed to consolidate providers, update our permissions and security protocols to be consistent with the importance of the website, and much more,” says John Howell, IT operations manager at Football Federation Australia. “The interface is user friendly and alerts us to where we need to keep watch or increase security. I’ve never seen anything like it before, and knowing I can chat with my CSC rep about any of the security blind spots that are revealed—and get protected right away—gives us peace of mind that our data and customers are protected.”

CSC Security Center helps clients reduce exposure to cyber crime by providing them a single view into all risk areas.

About CSC

CSC helps businesses thrive online. We help effectively manage, promote, and secure our clients’ valuable brand assets against the threats of the online world. Leading companies around the world choose us to be their trusted partner, including more than 65% of the Interbrand® 100 Best Global Brands. Leveraging state-of-the-art technology, Digital Brand Services delivers outstanding outcomes through our unique account management structure. With our expert, dedicated team, you’ll have a daily point of contact to ensure your brand has the strength it needs to succeed in the 21st century. We help consolidate and secure, monitor and enforce, then optimize and promote your brands to maximize your digital presence, secure your digital intellectual property, and reduce costs. CSC is the world’s leading provider of digital brand services to companies around the globe. Headquartered in Wilmington, Delaware, CSC also operates from offices throughout the U.S., Canada, Europe, and the Asia-Pacific region. Learn more at cscdigitalbrand.services .

Contact:

Laura Crozier Public Relations Manager, USA (302) 693-5401 x. 65526 laura.crozier@cscglobal.com

Marie Le Maitre Global Marketing Manager, EMEA +44 (0)20 75132324 marie.lemaitre@cscglobal.com

Letitia Thian Marketing Manager, APAC +65 6709 0104 x. 80104 letitia.thian@cscglobal.com

CSC ® News Room

Link:

ClickThru

Social Media:

https://www.facebook.com/CSCSince1899/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye